Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03155503 · ClinicalTrials.gov registry record · Phase 1
A Study to Investigate the Safety, Tolerability and Pharmacokinetics of SUVN-911 in Healthy Subjects
A Phase 1 study, sponsored by Suven Life Sciences Limited.
- Completed
- Registry status
- Phase 1
- Development phase
- 64
- Enrollment target
NCT03155503 is a Phase 1 study that has completed, run by Suven Life Sciences Limited. The registered enrollment target is 64 participants.
The verdict
NCT03155503, a Phase 1 study, has completed, sponsored by Suven Life Sciences Limited.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 64 participants
- Enrollment target
Study Summary
This is a Phase 1, conventional, double-blind, placebo-controlled, single-center clinical study comprised of 2 segments (Segment 1 and Segment 2) in which single and multiple doses of SUVN-911 or placebo will be orally administered to healthy male subjects to evaluate the safety, tolerability, and pharmacokinetic profile.
Interventions
- DRUG Placebo
- DRUG SUVN-911
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 64 participants |
| Start Date | 2017-05-22 |
| Est. Completion | 2018-03-14 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03155503
The ClinicalTrials.gov registry entry for NCT03155503 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 64 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Suven Life Sciences Limited, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03155503 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03155503 about?
NCT03155503 is a clinical study titled "A Study to Investigate the Safety, Tolerability and Pharmacokinetics of SUVN-911 in Healthy Subjects". This is a Phase 1, conventional, double-blind, placebo-controlled, single-center clinical study comprised of 2 segments (Segment 1 and Segment 2) in which single and multiple doses of SUVN-911 or placebo will be orally administered to healthy male subjects to evaluate the safety, tolerability, and p...
What is the current status of trial NCT03155503?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 64 participants. The study started on 2017-05-22. Estimated completion is 2018-03-14.
What interventions are being tested in trial NCT03155503?
The interventions under investigation include: Placebo (DRUG), SUVN-911 (DRUG).
Who is sponsoring clinical trial NCT03155503?
This trial is sponsored by Suven Life Sciences Limited, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.